{"id":26412,"date":"2022-10-07T10:00:00","date_gmt":"2022-10-07T08:00:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/?p=26412"},"modified":"2022-10-07T10:50:36","modified_gmt":"2022-10-07T08:50:36","slug":"gedeon-richter","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/gedeon-richter\/","title":{"rendered":"Gedeon Richter receives “The Most Innovative Product” award from gynaecologists for Ryeqo\u00ae and is ranked second in the Pharma Trend Ranking 2022\ufffc"},"content":{"rendered":"

\"\"<\/p>\n

The specialist group of gynaecologists awards Gedeon Richter 2022 for its preparation Ryeqo\u00ae with the award “The most innovative product”. In the interdisciplinary ranking “Best Pharmaceutical Companies in Germany”, Gedeon Richter moves up 5 places in the category “Large individual, medium-sized and international companies” in 2022 and takes 2nd place. InfectoPharm was ranked first and ALK-Abell\u00f3 third.
\n<\/p>\n

Gynaecologists surveyed in the Pharma Trend 2022 study see Ryeqo\u00ae as the most innovative product for the treatment of uterine fibroid. In this indication, 59% of the gynaecologists surveyed named novelty on the market, 54% an innovative active principle and 33% a new combination option as the most important criteria for their choice. Ryeqo\u00ae won the spontaneous vote with 63% compared to the monopreparation Esmya\u00ae, which received 10% of the votes – and, like Ryeqo\u00ae, comes from Gedeon Richter.<\/p>\n

Gedeon Richter: Europe’s Market Leader in Women’s Health<\/h2>\n

With a small pharmaceutical production in his Budapest pharmacy, Gedeon Richter laid the foundation stone in 1901 for a company that today has over 12,000 employees on five continents with 19 representative offices and 41 sales companies. The Hungarian company launched its first own oral contraceptive, Infecundin, in 1966. Products for gynaecology, cardiology and central nervous system now account for the lion’s share of annual sales, which amounted to \u20ac1.758 billion in 2021 (+11.3% year-on-year). 7% of products are sold in Hungary, 42% in Europe, 21% in Russia, Eastern Europe and Asia (Commonwealth of Independent States, CIS), 20% in USA. Revenues in Western Europe amounted to 198 million euros in 2021. Production facilities are located in Poland, Romania, Russia, India and Germany.<\/p>\n

Since 2011, the Group subsidiary Gedeon Richter Pharma GmbH has been represented in Germany with headquarters in Eschborn. Its focus is on contraceptives (including the product line purchased from Gr\u00fcnenthal), myoma therapy and hormone replacement therapy. Esmya\u00ae (Ulipristal) for the treatment of uterine fibroids was named the most innovative product by the gynaecologists in 2015. The biosimilar Terrosa\u00ae (teriparatide) for the treatment of osteoporosis is also a hormone derivative. In April 2018, Reagila\u00ae (cariprazine), a new atypical neuroleptic, was launched in Germany and the following year became the first antipsychotic to receive the Galenus von Pergamon Award in the “Specialist Care” category. The G-BA attested Reagila\u00ae an additional benefit in the long-term treatment of schizophrenia patients with predominantly negative symptoms. In July 2021 Richter launched Drovelis\u00ae, a pill containing the novel estrogen estetrol.<\/p>\n

As strategic pillars for the future, the annual report 2021 mentions the further marketing of Reagila\u00ae, original research (currently 10 projects), women’s health, biosimilars and generics. The Richter Group invests around 8.5% of its turnover in research and development (approx. 150 million euros in 2021). In a joint venture with the German Helm AG, Hamburg, Richter-Helm Biologics develops and produces biotechnological drugs and vaccines with 190 employees in Hamburg, Hanover and Bovenau.<\/p>\n

Gedeon Richter supports numerous initiatives and organisations active in healthcare, education and environmental protection.<\/p>\n

Ryeqo\u00ae: The most innovative product for gynaecologists<\/h2>\n

In Pharma Trend, Gedeon Richter has long been one of the most sustainable and innovative pharmaceutical companies in Germany among gynaecologists. The research-based company will receive the award “The Most Innovative Product” in 2022 for the oral Relugolix combination therapy with Ryeqo\u00ae. The special feature of Ryeqo\u00ae is a combination of active ingredients that addresses various aspects of uterine fibroids. In the Pharma Trend 2022 study, 41% of the gynaecologists surveyed highlighted the special combination option as a plus point, one in five (21%) saw it as an expanded spectrum of action or improved effect, and more than half (54%) praised the innovative active principle. A total of 68% welcomed the novelty on the market.<\/p>\n

Multiple awards for Gedeon Richter for innovation<\/h2>\n

Gedeon Richter has been awarded several times for innovation in the Rx category among gynaecologists since the start of the Pharma Trend benchmark study in 2000. In 2013 and 2015, the company received the award “The Most Innovative Product” for Esmya\u00ae, in 2022 for Ryeqo\u00ae.<\/p>\n

Awards for innovation and sustainability since 2000:<\/p>\n